TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03533426

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane catheter block
Description: Ultrasonographic guided placement of a catheter under the serratus anterior muscle in cases of open thoracotomies for chest malignancies in an attempt to reduce the emergence of postthoracotomy pain syndrome.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: The use of patient controlled analgesia through a pump aiming to reduce the development of postthoracotomy pain syndrome
Study: NCT03371810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: Mobile therapeutic light (10.000 LUX, white light without UV light), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total at home provided by a bright light therapy device (Philips EnergyLight HF 3419). Monitoring and feedback will be realized with the m-Health system comprising of a smartphone equipped with the m-Health App, and an activity sensor equipped with a light sensor to monitor the light exposure of the participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: During 10 weeks participants perform three days of aerobic activities proposed and in two of these days also do muscle-strengthening exercise. Specifically, a training day consists of: (i) a 5-min warm-up period, (ii) a 10-35 min of muscle-strength training on two of the three days, (iii) a 20-40 min of aerobic training, (iii), and a 5-min of flexibility/stretching cool-down. During the course of the 10 weeks, the duration and intensity of the exercises will increase gradually.~Instruction, monitoring, and feedback will be realised by the m-Health system including a smartphone equipped with the m-Health app and Secure Digital Memory cards to store the exercise videos as well as an activity sensor equipped with a mobile sensor for the acquisition of physical activity.
Study: NCT05521425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helping Hands for CAPD bag exchange procedures
Description: Training served as Treatment As Usual (TAU) for all participants; The difference between two groups was whether Helping hands were provided to participants for CAPD bag exchange procedures at home.
Study: NCT03077191

Intervention type: OTHER
Intervention: Quality of life measurement
Description: The quality of life of breast cancer patients treated with conservative surgery and adjuvant whole breast hypofractionated radiotherapy, without boost, will be evaluated.
Study: NCT02483897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5% ophthalmic drops
Description: 0.8 mls. drops provided to be used hourly p.r.n. for pain control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline placebo drops
Description: 0.8 mls. drops provided to be used hourly p.r.n. for pain control
Study: NCT04605848

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Infrared themrography
Description: measurement of temperature and microcirculation of the skin overlaying BAT depots in the region of FDG-uptake detected by 18F-FDG PET/CT before and after a cold test
Study: NCT04609267

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PHQ-9 - Mirror format
Description: The intervention we will be using is a new delivery system of the PHQ-9 using an Amazon Alexa equipped Mirror device. This Mirror device is similar to a smart television with a mirror interface. The device records auditory responses to the PHQ-9. We will be comparing the responses from the Mirror device to those given on the clinically established paper format.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PHQ-9 - Mirror format
Description: The intervention we will be using is a new delivery system of the PHQ-9 using an Amazon Alexa equipped Mirror device. This Mirror device is similar to a smart television with a mirror interface. The device records auditory responses to the PHQ-9. We will be comparing the responses from the Mirror device to those given on the clinically established paper format.
Study: NCT01269996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Janumet, Lantus
Description: In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Janumet, Lantus
Description: In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin, gliclazide, protaphane
Description: In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin, gliclazide, protaphane
Description: In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection.
Study: NCT01127282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin (vitamin A 15 mg,C 500 mg, E 400IU)
Description: Vitamin (vitamin A 15 mg,C 500 mg, E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (digestive tablet)
Description: Placebo (digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
Study: NCT02732379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lavender Aromatherapy
Description: the two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rose Aromatherapy
Description: the two drops of rose essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ginger Aromatherapy
Description: the two drops of ginger essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Aromatherapy
Description: the two drops of pure water will be dropped into the gauze and the patient will inhale it for 5 minutes
Study: NCT00523159

Intervention type: DRUG
Group type: OTHER
Intervention: Endoxana, IMA901, Leukine
Description: a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901

Intervention type: DRUG
Group type: OTHER
Intervention: IMA901 and Leukine
Description: Intradermal injection of GM-CSF followed by intradermal injection of IMA901
Study: NCT02621580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pan-Retinal Photocoagulation
Description: Diabetic retinopathy does not usually impair sight until the development of long-term complications, including proliferative retinopathy, a condition in which abnormal new blood vessels may rupture and bleed inside the eye. When this advanced stage of retinopathy occurs, pan-retinal photocoagulation is usually recommended.~During this procedure, a special laser is used to make tiny burns that seal the retina and stop vessels from growing and leaking. Hundreds of tiny spots of laser are placed in the retina to reduce the risk of vitreous haemorrhage and retinal detachment.
Study: NCT02110901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRT-201

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03638206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell immunotherapy
Description: According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
Study: NCT04667299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid
Study: NCT04577274

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: smoothie with regular formulas (SM)
Description: Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: smoothie with low carbohydrate formulas (SMLS)
Description: Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
Study: NCT04667299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: 0.6g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 0.4g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g qid
Study: NCT04577274

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: conventional diabetic enteral drinks (Glucerna)
Description: Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
Study: NCT04667299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1g bid
Study: NCT01844284

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE PRIME®/XIENCE Xpedition™
Description: Subjects receiving XIENCE PRIME®/XIENCE Xpedition™

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb™ BVS
Description: Subjects receiving Absorb™ BVS
Study: NCT04496102

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon
Description: Modern TKA design (Triathlon) with patellar resurfacing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triathlon
Description: Modern TKA design (Triathlon) with patellar resurfacing
Study: NCT04259450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14 mg AFM24
Description: 14 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg AFM24
Description: 40 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg AFM24
Description: 80 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160 mg AFM24
Description: 160 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 320 mg AFM24
Description: 320 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 480 mg AFM24
Description: 480 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 480 mg AFM24
Description: 480 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 480 mg AFM24
Description: 480 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 480 mg AFM24
Description: 480 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 720 mg AFM24
Description: 720 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
Study: NCT04475549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-6463 Tablets
Description: IW-6463 tablets administered orally (daily)
Study: NCT03670667

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT03383770

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia Touhy
Description: The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A touhy cannula is used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia Facet
Description: The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A facet cannula is used.
Study: NCT02563457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periodontal manual treatment
Description: periodontal manual treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no periodontal manual treatment
Description: blood sampling
Study: NCT01332409

Intervention type: DRUG
Intervention: Salmeterol and Fluticasone
Description: Administered according to the prescribing information in the locally approved label by the authorities.
Study: NCT00255931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy and Relaxation/biofeedback

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Placebo
Description: Untrained relaxation
Study: NCT04166253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Alfacalcidol oral tablets once daily
Study: NCT03044964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
Study: NCT03246282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVL1000 Treatment Station
Description: Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline 0.9% Infusion Solution Bag
Description: 250 ml of 0.9% Sodium Chloride Solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Catheterization
Description: 20-gauge 1.0 catheter
Study: NCT02362048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196 in combination with pembrolizumab
Study: NCT04137692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Blood Cell Transfusion
Description: The procedure will be performed as an outpatient according to protocols established for sickle cell anemia patients. Two IVs are placed for the purposes of transfusion, one for draw and one for return. Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.Total time of procedure: approximately 150 minutes.
Study: NCT01484548

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F3 + GLA-SE
Description: 20 ug of LEISH-F3 and 2 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F3 + GLA-SE
Description: 20 ug of LEISH-F3 and 5 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LEISH-F3 alone
Description: 20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
Study: NCT02142933

Intervention type: OTHER
Group type: OTHER
Intervention: vagino-perineal swab
Study: NCT00790010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Plus Ipilimumab Cohort 1
Description: Cohort 1: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Plus Ipilimumab Cohort 2
Description: Cohort 2: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Plus Ipilimumab Cohort 3
Description: Cohort 3: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Plus Ipilimumab Cohort 4
Description: Cohort 4: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
Study: NCT04602312

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Meditation (1 x 20-minute guided audio training)
Description: Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation (1 x 20-minute guided audio training)
Description: Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Meditation (1 x 20-minute guided audio training)
Description: Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
Study: NCT02853890

Intervention type: OTHER
Intervention: Questionnaires during hospitalization for delivery
Description: Questionnaires during hospitalization for delivery (one questionnaire completed by doctors about different technic of analgesia and anesthesia and one questionnaire completed by women about pain, and feeling about the different techniques of analgesia and anesthesia used during delivery, eventually caesarean section or uterine revision)
Study: NCT01492023

Intervention type: BEHAVIORAL
Intervention: neuropsychological rehabilitation
Description: attention retraining and teaching compensatory strategies as well as offering psychological support to better cope with cognitive impairments (13 times 60 minutes, once per week during 13 weeks)
Study: NCT00665574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActaVisc and ActaVisc Mx Intra-articular Injection
Description: ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActaVisc and ActaVisc Mx Intra-articular Injection
Description: ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ActaVisc and ActaVisc Mx Intra-articular Injection
Description: ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ActaVisc and ActaVisc Mx Intra-articular Injection
Description: ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.
Study: NCT02934074

Intervention type: OTHER
Intervention: No intervention
Study: NCT00491803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: sildenafil 20 mg orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: sildenafil 40 mg orally
Study: NCT03065270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use unstable shoes Masai Barefoot Technology (MBT)
Description: Use of unstable shoes during 9 weeks, at least four hours per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use conventional sport shoes
Description: Use of conventional sport shoes during 9 weeks, at least four hours per day.
Study: NCT01033357

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Graft, Vascular Wrap
Description: Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lifespan® ePTFE Vascular Graft Only
Description: Vascular Graft only